Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor plus cyclophosphamide and prednisolone vs cyclophosphamide and prednisolone in relapsed or refractory multiple myeloma
2017-001736-19Phase 2Unknown
- Sponsor
- University of Leeds
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of selinexor in multiple myeloma (MM) (2 arms), sponsored by University of Leeds. Primary endpoint: Progression-free survival at 6 months. Status: unknown.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-001736-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001736-19.